Pro-inflammatory tumor profile predicts PCR in NSCLC to neoadjuvant chemoimmunotherapy

Marta Casarrubios, MSc, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, talks on an analysis into pre-treatment tumor samples of patients from the Phase II NADIM (NCT03081689) trial undergoing neoadjuvant chemoimmunotherapy. A pro-inflammatory tumor profile in the pre-treatment samples of patients with complete pathological response (CPR) was found. The pro-inflammatory tumor profile may predict an effective immune response to nivolumab. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

• فئة